Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
ConclusionsRDW, a routinely available and inexpensive biomarker, provides incremental prognostic information when added to established predictors. Compared with valsartan, sacubitril/valsartan led to a small reduction in RDW. (Source: ESC Heart Failure)
Source: ESC Heart Failure - October 10, 2023 Category: Cardiology Authors: Jawad H. Butt,
Kirsty McDowell,
Toru Kondo,
Akshay S. Desai,
Martin P. Lefkowitz,
Milton Packer,
Mark C. Petrie,
Marc A. Pfeffer,
Jean L. Rouleau,
Muthiah Vaduganathan,
Michael R. Zile,
Pardeep S. Jhund,
Lars K øber,
Scott Solomon,
John J.V Tags: Original Article Source Type: research
Isovolumic Contraction Velocity in Heart Failure with Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: The PROVE-HF Study
To assess tissue Doppler-derived mitral annular isovolumic contraction velocity (ICV) after starting sacubitril/valsartan (sac/val) for the treatment of heart failure with reduced ejection fraction (HFrEF; left ventricular [LV] EF (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - October 8, 2023 Category: Cardiology Authors: Alaa Mabrouk Salem Omar, Sean Murphy, G. Michael Felker, Ileana Pi ña, Javed Butler, Yuxi Liu, Reza Mohebi, Kirtipal Bhatia, Jonathan H. Ward, Kristin M. Williamson, Scott D. Solomon, James L. Januzzi, Johanna Contreras Source Type: research
Nanotechnology-Based Strategies for Extended-Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review
Chem Biodivers. 2023 Oct 5:e202301157. doi: 10.1002/cbdv.202301157. Online ahead of print.ABSTRACTThere has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6% and 8% of pregnancies are affected by hypertension, which can adversely affect the mother and the fetus. Furthermore, a hypertensive individual is at increased risk of developing kidney disease, arterial hardening, eye damage, and strokes. Using angiotensin receptor blockers (ARBs) is widespread in treating hypertension, heart failure, coronary artery disease, and diabetic nephropathy....
Source: Chemistry and Biodiversity - October 5, 2023 Category: Biochemistry Authors: Bahareh Haji Ali Milad Shirvaliloo Sonia Fathi-Karkan Shekoufeh Mirinejad Fulden Ulucan-Karnak Saman Sargazi Sara Sargazi Roghayeh Sheervalilou Mohammed M Rahman Source Type: research
Adherence to drug therapy in patients with heart failure associated with reduced ejection fractions (HFrEF) during cardiac rehabilitation and after 3 and 6 Â months
DiscussionThese data illustrate the effect of rehabilitation in terms of optimizing drug therapy, which stabilized over the course of 6 Â months. Furthermore, only a few patients with the main diagnosis HFrEF are referred for cardiac rehabilitation, although it is an essential part of guideline-based therapy. (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - October 5, 2023 Category: Cardiology Source Type: research
Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure
Conclusions
Treatment with sacubitril/valsartan was associated with a low rate of adverse effects in this adult sRV cohort. Persisting improvement in 6-minute walking test distance, NT-proBNP levels and echocardiographic parameters of sRV function was observed in an on-treatment analysis and showed no differential response based on sex or anatomy. (Source: Heart)
Source: Heart - September 28, 2023 Category: Cardiology Authors: Nederend, M., Kies, P., Regeer, M. V., Vliegen, H. W., Mertens, B. J., Robbers-Visser, D., Bouma, B. J., Tops, L. F., Schalij, M. J., Jongbloed, M. R. M., Egorova, A. D. Tags: Congenital heart disease Source Type: research
The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
This study aimed to investigate the efficacy and safety of sacubitril/valsartan (S/V) in HFrEF patients with hypotension. We included 43 consecutive HFrEF patients with sBP  <  100 mmHg despite guideline-directed medical therapy for at least 3 months and who received S/V between September 2020 and July 2021. Patients admitted for acute heart failure were excluded and 29 patients were evaluated for safety endpoints. Furthermore, patients who performed non-pharmacologic al therapy or died within 1 month were excluded, finally, 25 patients were evaluated for efficacy endpoints. The mean initial S/V dose was 53.0 Â...
Source: Heart and Vessels - September 26, 2023 Category: Cardiology Source Type: research
Impact of sacubitril/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients
This study investigated whether ARNi and SGLT2i 1) improve the rate of clinical and echocardiographic CRT response and 2) have different impact based on the ischemic or non-ischemic etiology. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - September 23, 2023 Category: Cardiology Authors: Celeste Fonderico, Valerio Pergola, Daniele Faccenda, Alfonsomaria Salucci, Gianluigi Comparone, Aldo Marrese, Giuseppe Ammirati, Luigi Cocchiara, Alfonso Varriale, Giovanni Esposito, Antonio Rapacciuolo, Teresa Strisciuglio Source Type: research
Development and validation of a multivariate model for predicting heart failure hospitalization and mortality in patients receiving maintenance hemodialysis
CONCLUSION: The developed prediction model offered an accurate and personalized assessment of HF hospitalization risk and all-cause mortality in patients with MHD. It can be employed to identify high-risk patients and guide treatment and follow-up.PMID:37732398 | DOI:10.1080/0886022X.2023.2255686 (Source: Renal Failure)
Source: Renal Failure - September 21, 2023 Category: Urology & Nephrology Authors: Wenwu Tang Ying Zhang Zhixin Wang Xinzhu Yuan Xiaoxia Chen Xiaohua Yang Zhirui Qi Ju Zhang Jie Li Xisheng Xie Source Type: research
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin –angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples
ConclusionIn HFrEF patients treated with beta-blockers, sacubitril/valsartan is associated with a relative greater benefit in LV reverse remodeling indices than other RAS inhibitors.Graphical abstract (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - September 21, 2023 Category: Cardiology Source Type: research
Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure
In conclusion, significant LV reverse remodeling occurred after initiation of sacubitril/valsartan, even in HF patients with LVEF <  50% and systolic blood pressure ≤ 100 mmHg. (Source: Heart and Vessels)
Source: Heart and Vessels - September 21, 2023 Category: Cardiology Source Type: research
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin –angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples
ConclusionIn HFrEF patients treated with beta-blockers, sacubitril/valsartan is associated with a relative greater benefit in LV reverse remodeling indices than other RAS inhibitors.Graphical abstract (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - September 21, 2023 Category: Cardiology Source Type: research
